Evidence map›Paper›PMID 15742407›Full record

ArticleWorld journal of gastroenterology2005

Detection of CK20mRNA in peripheral blood of pancreatic cancer and its clinical significance.

Yun-Li Zhang, Jian-Guo Feng, Jian-Min Gou, Li-Xin Zhou, Ping Wang

Abstract read
In one paragraph

Article in World journal of gastroenterology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yun-Li ZhangDepartment of Hepato-Pancreatico-Billiary Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang Province, China. zylzrl@mail.hz.zj.cn
Jian-Guo Feng
Jian-Min Gou
Li-Xin Zhou
Ping Wang

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo detect the expression of CK20mRNA in peripheral blood of pancreatic cancer and evaluate its clinical significance.

methodsExpression of CK20mRNA in peripheral blood was detected by fluorogenic qualitative reverse transcription-polymerase chain reaction (RT-PCR) in 40 cases of pancreatic cancer at the night before operation, in 5 cases of benign pancreatic diseases, in 5 cases of healthy individuals. The relationships were investigated between CK20mRNA expression and the clinicopathological variables, and clinical follow-up outcome in those patients with pancreatic cancer having undergone radical resection.

resultsOf the 40 patients with pancreatic cancer, 23 (57.5%) cases were positive for CK20mRNA expression. CK20mRNA expression was significantly correlated with lymphatic metastasis (P = 0.008), histopathological grading (P = 0.009), and pathological stage (P = 0.021); there was no significant correlation between CK20mRNA expression and age, gender, tumor diameter, and depth of invasion. The cumulative metastasis rates of patients with CK20mRNA expression were higher than those of patients with no CK20mRNA expression within 6 mo (34.7% vs 5.9%, P = 0.043) or 12 mo (73.9% vs 35.3%, P = 0.02) after operation. CK20mRNA expression in peripheral blood of pancreatic cancer indicated poorer prognosis. The survival rate of patients with CK20mRNA expression was lower than that of patients with negative CK20mRNA expression (Log-Rank = 13.31, P = 0.0003).

conclusionCK20mRNA is a sensitive and specific molecular marker for the detection of micrometastasis in peripheral blood of patients with pancreatic cancer. The CK20mRNA expression in peripheral blood is correlated with biological characteristic of pancreatic cancer. It can help to predict the prognosis of pancreatic cancer after operation, and to determine which patient will benefit from aggressive adjuvant therapies.

Indexed as

AdultAgedBiomarkers, TumorFemaleFollow-Up StudiesHumansIntermediate Filament ProteinsKeratin-20MaleMiddle AgedPancreatic NeoplasmsPrognosisReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSurvival AnalysisBiomarkers, TumorIntermediate Filament ProteinsKeratin-20KRT20 protein, humanRNA, Messenger

Identifiers

PMID15742407
PMCPMC4250764

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.